Correction to: GDF5 as a rejuvenating treatment for age-related neuromuscular failure - Summary - MDSpire

Correction to: GDF5 as a rejuvenating treatment for age-related neuromuscular failure

  • November 20, 2024

  • 0 min

Share

Objective:

To correct author name reversals and minor errors in the originally published article.

Key Findings:
  • Author names were incorrectly presented in the original publication.
  • Minor grammatical and typographical errors were identified and corrected.
Interpretation:

The corrections enhance the accuracy and credibility of the published research.

Limitations:
  • The article does not provide new data or findings beyond the corrections.
Conclusion:

The publisher acknowledges the errors and has made necessary amendments to ensure the integrity of the publication.

Original Source(s)

Correction to: GDF5 as a rejuvenating treatment for age-related neuromuscular failure

  • November 20, 2024

Related Content

A Case Study and Literature Review on Type IV Spinal Muscular Atrophy with Gastrocnemius Pseudohypertrophy Due to SMN1 Gene Deletion

A Smarter Screen for Sleep Apnea Stimulation

A four-factor staging system stratified response rates from 90.9% to 37.5% in a retrospective cohort study, although the model showed only moderate discrimination (C statistic, 0.68) and requires external validation

FDA Monthly Preview: Key May Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.